PubMed · 10221290
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R Mahendran. 1999. Obsessive-compulsive symptoms with risperidone.. https://doi.org/10.4088/jcp.v60n0412b
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A specific, high performance liquid chromatographic method was developed for the assay of haloperidol, together with an adequate separation of its degradation products. The method is based on the use of an octadecylsilane stationary phase column under isocratic conditions. The mobile phase consisted of 50 mM sodium phosphate monobasic pH 2.5-acetonitrile-THF-TEA (63:34:3:0.1, v/v/v/v) adjusted with o-phosphoric acid to a pH of 2.5. The degradation was performed in hydrochloric acid, sodium hydroxide and hydrogen peroxide. The main degradation products were identified. Application of the assay of haloperidol in tablet formulations is presented.
The aim of this study was to evaluate the effectiveness of newer atypical antipsychotic drugs in comparison to clozapine for schizophrenia. Publications in all languages were searched from all relevant databases and all randomized controlled trials comparing clozapine with newer atypical drugs were included. The review and meta-analysis includes eight studies, most of them short in duration. Newer atypical drugs were broadly similar to clozapine when improvement was measured using a psychosis symptom rating scale or a global index. There was a trend for clozapine to be more effective than the others for positive symptoms, and less effective for the negative symptoms. The adverse effect profile of clozapine and newer atypical drugs was dissimilar: while clozapine produced more fatigue, hypersalivation, and orthostatic dizziness, new atypical drugs, with the exception of olanzapine, produced more extrapyramidal symptoms. As these results were obtained from few studies and a relatively small amount of patients, the equal effectiveness and tolerability of new atypical drugs in comparison with clozapine is not yet demonstrated. More trials of sufficient power, with longer duration, and measuring clinically important outcomes are urgently needed.
A rapid method for the determination of olanzapine in plasma using high-performance liquid chromatography with ultra violet detection is described. Olanzapine was extracted from plasma with a mixture of hexane/dichloromethane (85:15), and then back extracted into phosphate buffer pH 2.8. Separation was achieved on a RP Select B C(18) column and commonly administered drugs did not interfere with the assay. The limit of quantitation was 1.5 microg/l and the inter-day and intra-day relative standard deviations were less than 10%. Olanzapine was shown to be stable in plasma for up to 7 days when stored at 4 degrees C. Moreover, the addition of ascorbic acid was not necessary for the achievement of chemical stability during storage, or during the assay procedure. The method has been used to measure olanzapine concentrations in patients treated with various doses of the drug varying from 5 to 40 mg/day.